Double-blind Control Treatment of Huperzine-A and Placebo in 28 Patients with Alzheimer Disease
【Abstract in Chinese】 用国产胆碱酯酶抑制剂石杉碱甲片,以双盲法治疗28例(治疗组及对照组各14例,治疗组及对照组病例的性别、年龄、病程均无差异)Alzheimer(阿尔茨默)病.剂量为200μg,bid;疗程60d.用WMS评定疗效,治疗组治疗前后分别为51.4±14.1和61.8±15.9,对照组分别为35.6±16.2和37.0±11.4(P<0.005);两组有效率分别为71.4%和25.5%(P<0.005).另外,其他智能量表(HDS,MMSE)及日常生活量在(ADL)治疗前后对比,治疗组比对照组有明显的提高.治疗组中未见明显副作用.本文结果说明,石杉碱甲片对Alzheimer病改善记忆障碍及提高病人的生活功能有效,且片剂更便于病人的服用.
【Abstract】 A comparative study of therapeutic effect between home-made Huperzine-A tablet and placebo was conducted in 28 patients with Alzheimer diseases (AD). 28 patients were e-qually divided into two groups at random. The first group received Huperzine-A tablet and the other group was given placebo. The courses of treatment for two groups last for 60 days. The average doses for both groups were 600 μg/day. There were no significant differences in sex, age between two groups (P>0. 05). After treatment, mean scale score of Huperzine-A group was higher than the placebo group in HDS and MMSE. Moreover, the mean scale score in ADL of Huperzine-A group was lower than that in placebo group. No side effect was observed. It is suggested that Huperzine-A tablet was effective and safe for AD. The tablet of Huperzine-A was more convenient for clinical use in the AD patients.
- 【Source】 药物流行病学杂志 ,Chinese Journal of Pharmaco Epiolemiology , Editorial E-mail ,1995(04)
- 【CLC code】R749.1